---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Generic, brand name and therapeutic class of product"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Generic, brand name and therapeutic class of product. Topics: Manufacturer: Apnimed; Established name and proposed proprietary name; Therapeutic class: anti-apneic neuromuscular modulator combining an antimuscarinic and a norepinephrine reuptake inhibitor; Aroxybutynin: the R-enantiomer of oxybutynin, not previously approved. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/generic-brand-name-and-therapeutic-class-of-product"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Generic, brand name and therapeutic class of product

<a id="heading-2.1.2.1"></a>

## 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

### Manufacturer: Apnimed

> “AD109 is Apnimed’s investigational drug candidate, with a proposed proprietary name Oxnimbi.”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

> “Retain worldwide rights”

Source: [Apnimed presentation (2026)](https://ir.apnimed.com/static-files/69419ee6-af17-4ba9-9b99-4fccd6e88177)

<a id="topic-2.1.2.1-2"></a>

### Established name and proposed proprietary name

> “Our clinical product candidate, AD109 with a proposed proprietary name Oxnimbi”
> “(aroxybutynin and atomoxetine) tablets, for oral use”

Source: [Apnimed Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526462185/apmd-20260930.htm)

> “This brand name was conditionally approved by the FDA in May 2025, which was reconfirmed in June 2026, and is pending approval of the NDA in its totality.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “The proposed name remains subject to final FDA review and acceptance and may change.”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.2.1-3"></a>

### Therapeutic class: anti-apneic neuromuscular modulator combining an antimuscarinic and a norepinephrine reuptake inhibitor

> “is an investigational, fixed-dose anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor”

Source: [Apnimed Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526462185/apmd-20260930.htm)

> “It is a potentially first-in-class combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor.”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.2.1-4"></a>

### Aroxybutynin: the R-enantiomer of oxybutynin, not previously approved

> “Aroxybutynin (also known as R-oxybutynin) is a novel drug that, to our knowledge, has not previously been marketed or approved by the FDA or any other regulatory agency, for any indication.”
> “Oxybutynin is composed of an equal mixture of aroxybutynin and S-oxybutynin, i.e., it is a racemic mixture.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
